Views & Analysis | Perspectives on pharma industry issues

Oncology

On GDF-15 neutralisation and cachexia, with CatalYm

As ESMO 2026 continues to get underway, pharmaphorum web editor Nicole Raleigh spoke with Scott Clarke, CEO of CatalYm.

Oncology

pharmaphorum podcast Episode 282 at ESMO26: Dr Chuck Link, Syncromune

ESMO26: Lowering toxicity, extending lives, with Syncromune

As the ESMO26 Congress commences in Madrid, pharmaphorum invited Syncromune Executive Chairman Dr Chuck Link onto the podcast.

Oncology

Why precision biomarkers will change the future of breast ca...

Blood-based biomarkers can provide an earlier, dynamic view of what is happening inside a patient, creating an opportunity to detect changes sooner.

Sales & Marketing

Benefits of marketing with AI tools, upward trajectory graph

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Oncology

Sponsored

12 Questions with Julia Jakl

Learn more about Julia Jakl, VP and Business Unit Head, Oncology UK at GSK, in a new 12 Questions With.

Articles

Pharma sales part one – looking for a new role

Top sales performers are key to any pharma business model, discusses Marie Crespo in her first of two articles looking at the current situation within pharmaceutical sales. The last few years have placed pharma sales firmly under the spotlight. Indeed, some commentators are...

Articles

Pharma gets social: the world’s best social media of 2012?

Daniel Ghinn reminisces on his “Pharma gets social” monthly articles for the year of 2012 – a year in which pharma has begun to innovate within the digital and social media realm. As we head towards the end of a year in which we have seen digital channel use among pharmaceutical companies continue to...

Articles

Marketing modeling mix for pharma and budgeting for 2013

Rodica Ceslov explores the effective marketing modeling mixes for pharma in 2013. As pharmaceutical companies prepare to discuss allocations for 2013 budgets, many companies will be revising their current...

Sales & Marketing

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Sales & Marketing

Building a social presence inside regulatory guardrails

In the UK, promoting prescription-only medicines to the public is prohibited by law and by the ABPI Code - social media reactions and shares included.

Digital

Sponsored

Why AI transformation is really about people

Jeff Kaminski, global head of AI and data at Axtria and a former industry analyst, discusses culture, governance, and leadership challenges around AI.

Digital